- Reductions of up to 64 percent in triglycerides achieved - Reductions in atherogenic particles and increases in HDL particles observed - Data presented today at the American College of Cardiology My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about ISIS Download image Isis Pharmaceuticals, Inc. (PRNewsFoto/Isis Pharmaceuticals, Inc.) CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated...
↧